Research Signal – Source date 2023-08-04
Could the body’s daily timing patterns help clinicians recognize dementia earlier or more consistently? CIRCAME is a study involving patients from two memory clinics in Paris that investigates whether circadian-rhythm components and other personal factors could help distinguish different dementia diagnoses and stages of cognitive health.
The study record associated with August 4, 2023 describes a research direction, not a ready-to-use screening test. Its central question is whether information about roughly 24-hour biological patterns, along with sociodemographic, behavioral and health-related factors, might add useful information to assessment in primary care.
A daily pattern is not a diagnosis
Circadian rhythms are the body’s recurring patterns across roughly a 24-hour day. They are reflected in daily timing and related behaviors, including sleep and physical activity. CIRCAME is designed to examine these patterns alongside other information collected from people attending specialist memory clinics.
The registry description says the study would use baseline interviews and health-related measures, together with a wrist-mounted device to measure circadian rhythm and related behaviors. Other measures include reported sleep disturbance, retinal measures in the CIRCAME-EYE subsample, and audiological parameters in the CIRCAME-Ear substudy. These details describe what the study aims to measure and compare. They do not show that any particular rhythm pattern identifies dementia reliably.
The main objective is to look for associations between these factors and several kinds of dementia, while considering known sociodemographic and genetic risk factors. An association could make a factor worth investigating as part of a broader assessment. It would not, by itself, show that a disrupted rhythm causes dementia, that changing sleep prevents it, or that a wearable measure can diagnose someone.
Two kinds of dementia questions
CIRCAME keeps two different diagnostic dimensions in view. One concerns subtype: whether a clinical picture is associated with Alzheimer’s disease, Lewy body dementia, vascular dementia or frontotemporal dementia. The other concerns cognitive stage: whether participants are cognitively healthy, have mild cognitive impairment or have clinical dementia.
Subtype and stage answer different questions. A subtype concerns the kind of dementia being considered, while a stage describes where a person is along a broader cognitive course. Studying both could help researchers ask whether daily-rhythm components relate only to a general difference between healthier and more impaired cognition, or whether they also vary across the dementia categories named in the study.
The registry’s primary-care aim adds an important practical test. Memory-clinic patients have already reached a specialist setting where diagnosis can involve cognitive, behavioral and neuropsychological assessment, functional information and, in some cases, imaging or cerebrospinal-fluid biomarkers. A pattern observed in that setting would still need to show useful value among people encountered earlier in ordinary primary care.
Diagnosis now and progression later
The main question is about factors associated with diagnosis and stage at the time of assessment. A secondary objective looks further ahead: whether measured characteristics are associated with later cognitive decline, increasing limitations in daily activities, or progression to dementia among cognitively healthy participants and people with mild cognitive impairment.
The study record describes follow-up for up to 15 years after inclusion. That is a planned time horizon, not evidence that 15 years of observations had already occurred. The progression question also differs from the diagnostic one. Finding that a factor is associated with a diagnosis would not establish that it predicts future decline, and a factor associated with decline would not automatically become a useful screening measure.
For the same reason, the supplied evidence does not establish effect sizes, diagnostic accuracy or a validated screening tool. CIRCAME is described as an investigation into whether these measurements could be relevant to primary-care screening, not as a report that primary-care performance has already been demonstrated.
What this could mean for dementia screening
For patients, the potential benefit is a more accessible route to fuller dementia assessment. If daily-rhythm and personal-characteristic measures add useful information beyond known risk factors and perform adequately in primary care, clinicians could have another way to recognize people who need closer evaluation, including people who might otherwise remain outside specialist services.
That prospect depends on the measures carrying dependable information across the different diagnoses and cognitive stages the study considers, and on the findings transferring from two Paris memory clinics to primary-care settings. From the historical research perspective, CIRCAME therefore represents an attempt to examine whether an everyday biological pattern could contribute to recognition of dementia, not an achieved early-detection breakthrough or evidence of improved outcomes.
Key Sources
- Primary source: Circadian Rhythm and Other Factors in Memory Clinic Patients
Government or Regulator · Clinical Trial · 2023-08-04
Keep exploring